Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
46.73
+0.44 (0.95%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
289
Market Cap
5.57B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Apellis Pharmaceuticals | 1.00B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 4.04M |
SRRK News
- 11 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
- 4 weeks ago - Scholar Rock Holding Transcript: Status update - Transcripts
- 4 weeks ago - Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - Business Wire
- 6 weeks ago - Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Business Wire